Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Recursion Pharmaceuticals Inc Cl A (NQ: RXRX )

6.400 +0.080 (+1.27%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,630,491
Open 6.360
Bid (Size) 6.420 (1)
Ask (Size) 6.490 (2)
Prev. Close 6.320
Today's Range 6.335 - 6.580
52wk Range 5.035 - 15.74
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Is Recursion Pharmaceuticals a Millionaire-Maker Stock?
In an environment where the typical small biotech name is riskier than not, this one is curiously different. 
Via The Motley Fool
Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500
The Ark Innovation and Ark Genomic ETFs turn ten years old. A look at the annual returns and current top holdings. 
Via Benzinga
Topics ETFs Stocks
Exposures US Equities

Performance

YTD
-35.16%
-35.16%
1 Month
+5.61%
+5.61%
3 Month
-5.47%
-5.47%
6 Month
-28.41%
-28.41%
1 Year
+8.29%
+8.29%

More News

Read More
Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th
From Recursion Pharmaceuticals
Via GlobeNewswire
3 Key Trends That Are Bullish for Recursion Pharmaceuticals Stock
Via The Motley Fool
Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Is Recursion Pharmaceuticals Stock a Buy?
Via The Motley Fool
Prediction: These 2 Stocks Could Soar in 2025
Via The Motley Fool
Cathie Wood Is Betting on This AI Stock: Is It a Buy?
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Down 57% in 2024, Is Recursion Pharmaceuticals a Buy on the Dip?
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Via The Motley Fool
2 Artificial Intelligence Stocks That Could Deliver Explosive Gains
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Looking Into Recursion Pharmaceuticals's Recent Short Interest
Via Benzinga
Decoding 6 Analyst Evaluations For Recursion Pharmaceuticals
Via Benzinga
Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
2 Innovative Cathie Wood Stocks to Buy If You Can Stomach the Risk
Via The Motley Fool
AI-Focused Drug Discovery Stocks +6% Last Week Vs. -8% Previous Week
Via Talk Markets
AI-Focused Drug Discovery Stocks Portfolio -8% W/e Sept 6th
Via Talk Markets
These AI-Related Stocks Were Down +10% Week Ending September 6
Via Talk Markets
Topics Economy
Exposures Economy Interest Rates
Our AI-Focused Drug Discovery Stocks Portfolio Down 8% In August; Down 6.7% Yesterday Alone!
Via Talk Markets
Topics Economy
Exposures Economy
Crude Oil Dips Over 4%; SPAR Group Shares Spike Higher
Via Benzinga
Exposures Fossil Fuels
Nasdaq Dips Over 2%; US Construction Spending Falls In July
Via Benzinga
Recursion Pharmaceuticals Stock Is Sliding Tuesday: What's Going On?
Via Benzinga
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Is Recursion Pharmaceuticals a Warren Buffett Stock?
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.